Publication of information in CVMP agenda and minutes

Sonia Ribeiro, Head of Meeting Secretariat

Teresa Ferreira, CVMP Committee Manager

ISG meeting, 11 December 2025

Background

The Agency strives for openness and transparency in its activities ensuring the right balance between making information available in the interest of public health and protecting commercially confidential information.

The Agency reviewed the rules currently applied to CVMP agendas and minutes, to ensure compliance with the *Principles for publication of agendas and minutes of EMA scientific committees* and consistency with the rules followed by the other scientific committees.

As a result, intent to publish the following information as part of future CVMP agendas/minutes:

- **INN and proposed indication for veterinary marketing authorisation applications (MAA)**
- **Proposed indication for extension of indication applications**
- **INN and proposed indication for accelerated assessment request**

Examples

Current published information	Information proposed to be published
2.1.1 EMEA/V/C/0005890/0000 – cats	2.1.1 relfovetmab EMEA/V/C/0005890/0000 – cats Indication: For the alleviation of pain associated with osteoarthritis in cats
3.1.1 Bravecto TriUNO – fluralaner / moxidectin / pyrantel – EMA/VRA/0000263135 – dogs Variation requiring assessment: change(s) to therapeutic indication(s) - addition of a new therapeutic indication or modification of an approved one.	3.1.1 Bravecto TriUNO – fluralaner / moxidectin / pyrantel – EMA/VRA/0000263135 – dogs Variation requiring assessment: change(s) to therapeutic indication(s) - addition of a new therapeutic indication or modification of an approved one: treatment of infections with *Angiostrongylus vasorum*.

To be published at all stages of the procedure:
LoQ, LoOI, Opinion

Examples

Current published information	Information proposed to be published
-	9.2.2 Decision on the accelerated assessment request - Bluetongue virus, serotype 3, BTV-3/NET2023 Decision on accelerated assessment request for Bluetongue virus, serotype 3, BTV-3/NET2023 **Proposed indication**: Sheep: For active immunisation of sheep to reduce viraemia, mortality, clinical signs and lesions caused by bluetongue serotype 3. Onset of immunity: 4 weeks after completion of the primary vaccination scheme. Cattle: For active immunisation of cattle to reduce viraemia caused by bluetongue serotype 3. Onset of immunity: 3 weeks after completion of the primary vaccination scheme.

To be published for all accelerated assessment requests

Next steps

- The Agency considers this increased transparency for CVMP agendas/minutes is in the interest of public health and in line with the principles for publication of agendas and minutes of EMA scientific committees.
- The Agency intends to apply the new approach as of January 2026 CVMP agendas/minutes.
- The Agency welcomes any comments or feedback on the proposal from Industry stakeholders.

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Thank you

sonia.ribeiro@ema.europa.eu

Follow us